Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPAN-PD phase 3 trial of CVT-301 for OFF episodes in Parkinson's disease
2015-005067-17Phase 3Completed
- Sponsor
- Civitas Therapeutics
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing CVT-301 with Placebo (2 arms). Primary endpoint: Change from pre-dose in UPDRS Part 3 motor score at 30 minutes post-dose. Started Jan 2016; status: completed.
02
Drugs
levodopa inhalation powder
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2015-005067-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005067-17.